$1000 Invested In This Stock 15 Years Ago Would Be Worth $26,000 Today

7/19/24 4:00:25 PM ET

Medical/Dental Instruments

Health Care

Get the next $PODD alert in real time by email

Insulet (NASDAQ:PODD) has outperformed the market over the past 15 years by 12.29% on an annualized basis producing an average annual return of 24.43%. Currently, Insulet has a market capitalization of $13.66 billion.

Buying $1000 In PODD: If an investor had bought $1000 of PODD stock 15 years ago, it would be worth $26,248.99 today based on a price of $195.03 for PODD at the time of writing.

Insulet's Performance Over Last 15 Years

comp_fig

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Get the next $PODD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PODD

Date	Price Target	Rating	Analyst
11/6/2024	$300.00	Outperform	Bernstein
5/30/2024	$235.00	Buy	Redburn Atlantic
5/7/2024	$200.00	Peer Perform → Outperform	Wolfe Research
12/21/2023	$180.00 → $238.00	Neutral → Outperform	Robert W. Baird
12/4/2023	$185.00 → $234.00	Equal-Weight → Overweight	Morgan Stanley
10/2/2023	$260.00 → $240.00	Hold → Buy	Jefferies
8/21/2023	$320.00 → $219.00	Outperform → Neutral	Robert W. Baird
8/21/2023	$273.00 → $265.00	Neutral → Buy	Citigroup

More analyst ratings

$PODD
Financials

Live finance-specific insights

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)
Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. "We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chief Executive Officer. "Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication. Insulet leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of ou
11/7/24 4:01:00 PM ET
$PODD
Medical/Dental Instruments
Health Care
Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203
9/30/24 6:00:00 AM ET
$PODD
Medical/Dental Instruments
Health Care
Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year
Raising Full Year Revenue, Gross Margin and Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of $488.5 million, up 23.2%, or 23.4% in constant currency1, compared to $396.5 million in the prior year, exceeds the high end of the Company's guidance range of 18% in constant currency due to revenue outperformance for all product lines Total Omnipod revenue of $480.4 million, an increase of 26.3%, or 26.5% in constant curr
8/8/24 4:01:00 PM ET
$PODD
Medical/Dental Instruments
Health Care

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S. "We are excited to announce that Omnipod 5, the only AID system indicated for both type 1 and type 2 diabetes, is now integrated with Abbott's FreeStyle Libre 2 Plus sensor in the U.S. This latest innovation will allow millions of Americans who take insulin the ability to get started on Pod th
11/20/24 8:30:00 AM ET
$PODD
Medical/Dental Instruments
Health Care
Insulet to Present at Upcoming Investor Conferences
Insulet Corporation (NASDAQ:PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at three upcoming investor conferences (all Eastern Time): The 6th Annual Wolfe Research Healthcare Conference in New York City on Wednesday, November 20, 2024 at 12:00 p.m. The Nasdaq 51st Investor Conference in London on Tuesday, December 10, 2024 at 5:30 a.m. The J.P. Morgan 43rd Annual Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 6:45 p.m. To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will als
11/15/24 6:00:00 AM ET
$PODD
Medical/Dental Instruments
Health Care
Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)
Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. "We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chief Executive Officer. "Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication. Insulet leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of ou
11/7/24 4:01:00 PM ET
$PODD
Medical/Dental Instruments
Health Care

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
10/18/24 9:00:00 AM ET
$ENV
$LH
$MASI
$MSCI
Business Services
Consumer Discretionary
Medical Specialities
Health Care
Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors
Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl
7/25/24 8:00:00 AM ET
$EXAS
$PODD
Medical Specialities
Health Care
Medical/Dental Instruments
CereVasc Announces Appointments of New Directors
Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of DirectorsBOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following appointments to the Company's Board of Directors, effective July 11, 2024: Shlomi Nachman, former Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sectorTimothy Scannell, former President and Chief Operating Officer of Stryker"We are excited
7/16/24 8:45:00 AM ET
$NVCR
$PODD
Medical/Dental Instruments
Health Care

$1000 Invested In This Stock 15 Years Ago Would Be Worth $26,000 Today

Insulet's Performance Over Last 15 Years

Chat with this insight

Recent Analyst Ratings for $PODD

$PODD Financials

Live finance-specific insights

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024

Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year

$PODD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Insulet Corporation

Amendment: SEC Form SC 13G/A filed by Insulet Corporation

SEC Form SC 13G/A filed by Insulet Corporation (Amendment)

$PODD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$PODD Press Releases

Fastest customizable press release news feed in the world

Bernstein initiated coverage on Insulet with a new price target

Redburn Atlantic initiated coverage on Insulet with a new price target

Insulet upgraded by Wolfe Research with a new price target

Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.

Insulet to Present at Upcoming Investor Conferences

Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)

$PODD SEC Filings

Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Insulet Corporation

Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$PODD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

$PODD Leadership Updates

Live Leadership Updates

$PODD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

CereVasc Announces Appointments of New Directors

Director Borio Luciana sold $139,598 worth of shares (508 units at $274.80), decreasing direct ownership by 15% to 2,790 units (SEC Form 4)

Director Hopfield Jessica exercised 7,628 shares at a strike of $29.87 and sold $1,718,283 worth of shares (7,628 units at $225.26) (SEC Form 4)

Director Scannell Timothy J sold $1,129,200 worth of shares (5,000 units at $225.84), decreasing direct ownership by 14% to 30,586 units (SEC Form 4)

$PODD Market Insights

Live Market Insights

A Closer Look at 7 Analyst Recommendations For Insulet

Canaccord Genuity Maintains Buy on Insulet, Maintains $234 Price Target